Company
Kyowa Kirin
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
3 still marketed
Novel approvals
4
Approvals since 2021
1
Originals and new uses
Phase 3 trials
65
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Crysvita new use OrphanApr 23, 2026
- Crysvita new use Priority reviewOrphanJun 18, 2020
- Crysvita new use OrphanSep 27, 2019
- Crysvita new use Priority reviewOrphanSep 27, 2019
- Nourianz approved NovelAug 27, 2019
- Poteligeo approved NovelBreakthrough therapyPriority reviewOrphanAug 8, 2018
- Crysvita approved NovelBreakthrough therapyPriority reviewOrphanApr 17, 2018
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (3)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.